



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Mizolastine

Cat. No.:	HY-B0164												
CAS No.:	108612-45-9												
Molecular Formula:	C ₂₄ H ₂₅ FN ₆ O												
Molecular Weight:	432.49												
Target:	Histamine Receptor												
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>2 years</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 year</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	2 years		-20°C	1 year
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	2 years											
	-20°C	1 year											



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (57.80 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.3122 mL	11.5610 mL	23.1219 mL
	5 mM	0.4624 mL	2.3122 mL	4.6244 mL
	10 mM	0.2312 mL	1.1561 mL	2.3122 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Mizolastine is an orally active, high affinity and specific peripheral histamine H₁ receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticaria^{[1][2][3]}.

In Vitro

Mizolastine (1-10000 nM; 0.5-6 h) shows inhibitory effects on VEGF, KC and TNF-α release in mast cells^[1]. Mizolastine (0.1 μM; 4 h) significantly reduces VEGF165, VEGF120, TNF-α and KC mRNA expression in mast cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Mast cells (from Kunming mice)
Concentration:	1-10000 nM
Incubation Time:	0.5-6 h
Result:	Markedly inhibited release of KC, VEGF and TNF- α in a time- and dose- dependent manner.

RT-PCR^[1]

Cell Line:	Mast cells (from Kunming mice)
Concentration:	0.1 μ M
Incubation Time:	4 h
Result:	Led to a significant reduction of induced VEGF165, VEGF120, TNF- α and KC mRNA synthesis.

In Vivo

Mizolastine (0.3 mg/kg; p.o.; single daily for 7 days) inhibits production of 5-LOX AA (arachidonic acid) metabolite leukotriene B4 (LTB4), and suppresses expression of 5-LOX, cytosolic PLA2 (cPLA2), 5-LOX-activating protein, and LTB4 receptor mRNA in the AA-induced inflammation model^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (specific-pathogen-free; 234-254 g; 7 to 8-week-old; rat paw edema model) ^[2] .
Dosage:	0.3 mg/kg
Administration:	Oral gavage; single daily for 7 days.
Result:	Significantly reduced paw edema by 21% at 1 h, and by 14-18% between 2 and 4 h. Inhibited inflammatory cell infiltration and significantly reduced levels of LTB4. Suppressed expression of 5-LOX, cPLA2, FLAP and LTB4r mRNA.

REFERENCES

[1]. Xia Q, et al. The effect of mizolastine on expression of vascular endothelial cell growth factor, tumour necrosis factor-alpha and keratinocyte-derived chemokine in murine mast cells, compared with dexamethasone and loratadine. Clin Exp Dermatol. 2005 Mar

[2]. Ren X, et al. The anti-inflammatory effects of Yunnan Baiyao are involved in regulation of the phospholipase A2/arachidonic acid metabolites pathways in acute inflammation rat model. Mol Med Rep. 2017 Oct;16(4):4045-4053.

[3]. Prakash A, et al. Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria. BioDrugs. 1998 Jul;10(1):41-63.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA